Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma
| Autor: | Jeffrey Raizer, Kevin Laubscher, Robert Miday, Paola Canelos, Rajesh Narwal, Marc C. Chamberlain, Surasak Phuphanich, Minal Nade, Shengyan Hong |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Nausea Phases of clinical research Antibodies Monoclonal Humanized Gastroenterology Disease-Free Survival 03 medical and health sciences Young Adult 0302 clinical medicine Antineoplastic Agents Immunological Internal medicine medicine Clinical endpoint Humans Progression-free survival Adverse effect Survival rate Aged Temozolomide business.industry Brain Neoplasms Middle Aged Magnetic Resonance Imaging United States Surgery 030104 developmental biology Treatment Outcome Neurology Oncology Tolerability 030220 oncology & carcinogenesis Female Neurology (clinical) medicine.symptom Neoplasm Recurrence Local business Glioblastoma medicine.drug |
| Zdroj: | Journal of neuro-oncology. 131(1) |
| ISSN: | 1573-7373 |
| Popis: | MEDI-575, an immunoglobulin G2κ monoclonal antibody, selectively binds to platelet-derived growth factor-α receptor (PDGFR-α) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25 mg/kg intravenously over 60 min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability. PDGFR-α expression was evaluated by immunohistochemistry. Fifty-six patients were enrolled; median age was 56.5 years (range 23–79), 66 % were male, and 66 % were aged ≥65 years. PFS-6 was 15.4 % [90 % confidence interval (CI) 8.1–24.9]. No complete or partial responses were observed; 23 (41.1 %) patients had stable disease as best response. Median PFS was 1.4 months (90 % CI 1.4, 1.8); median OS was 9.7 months (90 % CI 6.5, 11.8). The most common treatment-related adverse events (AEs) were diarrhea (16 %), nausea (13 %), and fatigue (13 %). Twelve (21 %) patients reported grade ≥3 AEs, with hydrocephalus (n = 3), dysphagia (n = 2), and convulsion (n = 2) reported in more than 1 patient. Two patients had treatment-related Grade ≥3 AEs of decreased lymphocyte count and asthenia (n = 1 each). Seven patients (13 %) discontinued MEDI-575 owing to AEs. Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblastoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink